About this trial
This clinical trial aims to compare the skeletal and dental effects of conventional Hyrax expanders and 3D-printed Hyrax expanders in adolescent patients with maxillary transverse deficiency. Using cone-beam computed tomography (CBCT) and digital models, the study evaluates the precision, customization, and treatment outcomes of both appliance types to inform evidence-based orthodontic treatment planning.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Patients aged between 12 to 17 years.
Skeletal age ranges from CVMS 3 to CVMS 5.
Skeletal maxillary transverse deficiency with/without crossbite.
Cooperative and able to attend follow-up visits.
Disqualifiers
Previous orthodontic treatment.
Craniofacial syndromes, or cleft lip and/or palate.
Patients with vertical growth pattern.
Very bad oral hygiene and active periodontal disease.
Trial design
Parallel
Treatments tested in this trial
Three dimensionally printed hyrax expander
DeviceGroup A : A 3D-printed Hyrax expander designed for rapid maxillary expansion in orthodontic treatment. The device is manufactured using additive manufacturing technology for a customized fit.
Conventionally Fabricated Hyrax Expander
DeviceGroup B: A conventionally fabricated Hyrax expander used for rapid maxillary expansion . The device is made using traditional laboratory techniques.
Treatment groups
Trial outcomes
Primary outcomes
Amount of mid-palatal suture opening.
The amount of suture separation measured in millimeters in the axial plane through CBCT X-ray
Secondary outcomes
Amount of dental expansion
Dental expansion will be measured as changes in inter-canine width and intermolar width (in millimeters) on digital dental models.
The amount of tipping of maxillary molars and premolars.
Buccolingual tipping of maxillary molars and premolars will be quantified as angular changes measured on CBCT by comparing pre-expansion and post-expansion images.
Change of buccal alveolar bone thickness.
Changes in buccal alveolar bone thickness in millimeters will be measured on pre-expansion and post-expansion CBCT scans.
Pain assessment
Evaluating the pain experienced during the active expansion phase using the Visual Analogue Scale (VAS; 0-100 mm), where 0 mm represents no pain and 100 mm represents the worst imaginable pain; the higher the value in the VAS scale, the more severe the pain.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.